{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:02:10Z","timestamp":1790096530221,"version":"4.0.1"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,7,18]],"date-time":"2005-07-18T00:00:00Z","timestamp":1121644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The authors evaluated the safety, tolerability, and efficacy of treatment using lonafarnib, a novel farnesyltransferase inhibitor (FTI), in combination with paclitaxel in patients with metastatic (Stage IIIB\/V), taxane\u2010refractory\/resistant nonsmall cell lung carcinoma (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with NSCLC who experienced disease progression while receiving previous taxane therapy or who had disease recurrence within 3 months after taxane therapy cessation were treated with continuous lonafarnib 100 mg orally twice per day beginning on Day 1 and paclitaxel 175 mg\/m<jats:sup>2<\/jats:sup> intravenously over 3 hours on Day 8 of each 21\u2010day cycle.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A total of 33 patients were enrolled, 29 of whom were evaluable for response. Partial responses (PR) and stable disease (SD) were observed in 3 (10%) and 11 patients (38%), respectively. Thus, 48% (14 of 29) experienced clinical benefit (PR or SD). The updated and final median overall survival time was 39 weeks and the median disease progression\u2010free survival time was 16 weeks. The combination of lonafarnib and paclitaxel was well tolerated with minimal toxicity. Grade 3 toxicities included fatigue (9%), diarrhea (6%), and dyspnea (6%). Grade 3 neutropenia occurred in only 1 patient (3%). Grade 4 adverse events included respiratory insufficiency in 2 patients (6%) and acute respiratory failure in 1 patient (3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Lonafarnib plus paclitaxel demonstrated clinical activity in patients with taxane\u2010refractory\/resistant metastatic NSCLC. In addition, the combination of lonafarnib and paclitaxel was well tolerated with minimal toxicity. Evaluation of this combination therapy in additional clinical trials is warranted. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21188","type":"journal-article","created":{"date-parts":[[2005,7,18]],"date-time":"2005-07-18T10:56:47Z","timestamp":1121684207000},"page":"561-569","source":"Crossref","is-referenced-by-count":93,"title":["Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane\u2010refractory\/resistant nonsmall cell lung carcinoma"],"prefix":"10.1002","volume":"104","author":[{"given":"Edward S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill S.","family":"Kies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank V.","family":"Fossella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie S.","family":"Glisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zaknoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Statkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald F.","family":"Munden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Summey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.W.","family":"Pisters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vali","family":"Papadimitrakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Tighiouart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Rogatko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadlo R.","family":"Khuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,7,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.1.8"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.4.633"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-419X(97)00011-5"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-78267-1_22"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3631"},{"key":"e_1_2_5_7_2","first-page":"4682","article-title":"ras oncogenes in human cancer: a review","volume":"49","author":"Bos JL","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008303230902"},{"key":"e_1_2_5_9_2","first-page":"2407","article-title":"Prognostic impact of mutated K\u2010ras in surgically resected non\u2010small cell lung cancer patients","volume":"8","author":"Rosell R","year":"1993","journal-title":"Oncogene."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.14.6403"},{"key":"e_1_2_5_11_2","first-page":"4947","article-title":"Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap\u2010ras transgeneic mice","volume":"58","author":"Liu M","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_5_12_2","first-page":"5896","article-title":"Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models","volume":"59","author":"Nielsen LL","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003469200"},{"key":"e_1_2_5_14_2","first-page":"1438","article-title":"Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines","volume":"7","author":"Adjei AA","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.4.1369"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800000170"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1167"},{"key":"e_1_2_5_18_2","first-page":"1871","article-title":"A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity","volume":"60","author":"Adjei AA","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0412"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2000.5076"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.040546297"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006213200"},{"key":"e_1_2_5_23_2","first-page":"4666","article-title":"Dephosphorlyation and down\u2010regulation of AKT is associated with farnesyltransferase inhibitor (SCH66336) treatment in head and neck squamous cell carcinoma cell lines","volume":"943","author":"Hassan KA","year":"2002","journal-title":"Proc Am Assoc Cancer Res."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.075"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-7304(11)70674-X"},{"key":"e_1_2_5_26_2","first-page":"717","volume-title":"Cancer chemotherapy and biological response modifiers, annual 20","author":"Massarelli E","year":"2002"},{"key":"e_1_2_5_27_2","first-page":"1204","article-title":"Epidermal growth factor receptor\u2010targeted therapy with humanized chimeric monoclonal antibody, C225 in combination with cisplatin in patients with head and neck cancer","volume":"7","author":"Shin DM","year":"2001","journal-title":"Clin Cancer Res."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21188","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:50:22Z","timestamp":1760291422000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,18]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1002\/cncr.21188"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21188","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,18]]}}}